Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Inclusion Criteria

Informed subject consent will be obtained from those patients meeting the following
inclusion criteria:

- Male and female patients 18 years or older.

- Clinical and/or histopathological diagnosis of PRP

- Candidate for systemic therapy (PASI ≥ 10)

- Body surface area of involvement ≥ 10%

- Good general health as confirmed by medical history

- Patients who are willing and capable of cooperating to the extent and degree required
by the protocol; and

- Patients who read and sign an approved informed consent for this study

Exclusion Criteria

Patients are to be excluded based on the following criteria:

- Vulnerable study population

- Pregnant or nursing women

- Women planning a pregnancy within the study period

- Human immunodeficiency virus (HIV) positivity

- Known history of adverse reaction to Cosentyx

- Known history of hepatitis B, hepatitis C, or tuberculosis

- Personal or family history of inflammatory bowel disease